All
Cheson Considers the Most Effective Therapeutic Strategies for Patients With Follicular Lymphoma
March 27th 2018Bruce D. Cheson, MD, recently shared the treatment options and decisions he makes when treating patients with follicular lymphoma based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspective presentation.
Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC
March 27th 2018The treatment landscape of non-small cell lung cancer has been identifying the importance of immunotherapy already, but combination therapies will soon play a large role in treatment of these patients as well, according to Chad Pecot, MD.
Enfortumab Vedotin Granted FDA's Breakthrough Designation for Treatment of Urothelial Carcinoma
March 26th 2018Enfortumab vedotin has been granted a breakthrough therapy designation by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy. These findings have been released by Seattle Genetics and Astellas, the manufacturers of the antibody-drug conjugate.
Study Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC
March 26th 2018According to findings from the phase III IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.
MURANO Trial Results Demonstrate PFS Benefit with Venetoclax/Rituximab
March 24th 2018According to findings from the phase III MURANO trial recently published in the<em> New England Journal of Medicine, </em>the venetoclax (Venclexta) plus rituximab (Rituxan) regimen lowered the risk of disease progression or death by 83% in comparison with bendamustine (Treanda) plus rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic leukemia<em>.</em>
Expert Discusses Potential Expansions to the Treatment Landscape in RCC
March 23rd 2018Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with <em>Targeted Oncology</em>, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.
Nilotinib Granted FDA Approval for Pediatric CML
March 22nd 2018Based on data from 2 clinical trials, nilotinib (Tasigna) has been approved by the FDA for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.
Bendell Takes the Helm as Chief Development Officer at Sarah Cannon
March 22nd 2018Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.
Combination of Atezolizumab and Cobimetinib Active in mCRC
March 22nd 2018The combinations of atezolizumab and cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer. Results from a 2-stage phase Ib study presented at the 2018 Gastrointestinal Cancers Symposium demonstrated an overall response rate of 8% (n = 7). All responses were partial responses.
Earlier Pseudoprogression Seen in Patients With Oligodendroglioma Treated With Proton Therapy
March 21st 2018Patients with oligodendroglioma developed pseudoprogression earlier after treatment with proton therapy compared with after photon therapy, according to the results of a retrospective study comparing the rates of pseudoprogression that occurred in patients with anaplastic gliomas following treatment with different radiation therapy modalities.
TTFields with Temozolomide Recommended by NCCN for Newly Diagnosed GBM
March 21st 2018The combination of TTFields and temozolomide has been added by the NCCN to its guidelines for Category 1 treatment for patients with newly diagnosed glioblastoma, following maximal safe resection and completion of radiation therapy.
Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma
March 20th 2018Based on findings from the phase III ECHELON-1 trial, brentuximab vedotin (Adcetris) has been approved by the FDA for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.
PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo
March 20th 2018According to topline findings from the phase III IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.
Enzalutamide Granted FDA's Priority Review for Nonmetastatic CRPC
March 20th 2018Based on data from the phase III PROSPER trial, a supplemental new drug application for enzalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer has been granted a priority review by the FDA, according to Pfizer and Astellas, the companies developing the antiandrogen agent.
Certain Breast Cancer Patients Find Endocrine Therapy Ideal
March 20th 2018Tumor reduction for patients with ER-positive breast cancer can be achieved with endocrine therapy and can possibly avoid the need for chemotherapy or even surgery in some patients. Hyman B. Muss, MD, who presented at the 2018 Miami Breast Cancer Conference, said that deciding how long to continue this therapy can be tricky, however.
Results Show HER2 Mutations Cause Endocrine Resistance in ER+ Breast Cancer
March 19th 2018Uttara Nayar, PhD, shares the findings of recent studies in patients with ER+ breast cancer. Findings have shown that acquired HER2 mutations lead to endocrine resistance, the most frequent cause of breast cancer mortality in the country.
Marshall Highlights Treatment Options for Left-Sided mCRC
March 16th 2018John Marshall, MD, recently discussed the treatment options and decisions he makes when treating patients with metastatic colorectal cancer. Marshall explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
EBRT Shows Promise in Relapsed/Refractory Follicular Lymphoma
March 16th 2018External beam radiation therapy can be effective when integrated in a multimodality treatment strategy for patients with relapsed/refractory follicular lymphoma, according to findings from a small, retrospective study.
Erdafitinib Granted Breakthrough Therapy Designation by FDA for Urothelial Carcinoma
March 15th 2018Based on the phase II study BLC2001, erdafitinib has been granted a breakthrough therapy designation by the FDA for the treatment of metastatic urothelial carcinoma, according to Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor.
Paner Details the Current Landscape for Multiple Myeloma
March 15th 2018Agne Paner, MD, recently shared the treatment considerations and decisions she makes when treating patients with multiple myeloma. Paner, an assistant professor of medicine at Rush University Medical Center, Chicago, Illinois, explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.
Landgren Touches Upon Promising New Studies in the Field of Multiple Myeloma
March 14th 2018C. Ola Landgren, MD, PhD, recently shared the treatment considerations and decisions he makes when treating patients with newly diagnosed multiple myeloma. Landgren, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, explained how he would treat these patients based on the review of a case scenario during a <em>Targeted Oncology </em>live case-based peer perspectives dinner discussion.
Expert Discusses PARP Inhibitor Explosion in Treatment Landscape of Ovarian Cancer
March 14th 2018The use of immunotherapy agents for the treatment of gynecologic cancers is currently a hot topic in the field, with various clinical trials ongoing. The success of PARP inhibitors has also exploded over the past year, translating to improvements in progression-free survival and quality of life for some patients, says Erin K. Crane, MPH, MD.
FDA Places Hold on Axalimogene Filolisbac Plus Durvalumab Trial in Cervical, Head and Neck Cancer
March 14th 2018The FDA has placed a clinical hold on a phase I/II study of axalimogene filolisbac and durvalumab, according to an announcement by Advaxis, the manufacturer of axalimogene filolisbac, in a quarterly earnings report.The study is evaluating the combination in patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma.
Edward Wolin to Direct Neuroendocrine Center at Tisch Cancer Institute
March 14th 2018Edward M. Wolin, MD, has been named the director of the Center for Carcinoid and Neuroendocrine Tumors at The Tisch Cancer Institute of Mount Sinai Health System. He will also serve as a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai.
Pereira Offers View on Maintenance Therapy for Patients with Multiple Myeloma
March 13th 2018Denise. L. Pereira, MD, recently shared the treatment considerations and decisions she makes when treating patients with multiple myeloma. Pereira, assistant professor of clinical medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.